Amanta Healthcare Ltd Hits All-Time Low Amidst Persistent Market Pressures

Stock Performance and Market Context

On the day of the new low, Amanta Healthcare’s share price fell by 0.70%, slightly outperforming the Sensex’s decline of 1.08%. However, the stock has consistently lagged behind the benchmark over longer periods. Over the past week, it dropped 2.46% compared to the Sensex’s 4.98% fall, and over one month, it declined 8.76% against the Sensex’s 9.13% loss. The three-month performance shows a 6.47% decrease, while the Sensex fell 10.83% in the same period. Year-to-date, the stock is down 8.92%, marginally outperforming the Sensex’s 10.78% decline.

Despite these declines, the stock’s one-year, three-year, five-year, and ten-year returns have remained flat at 0.00%, contrasting sharply with the Sensex’s positive returns of 2.71%, 28.58%, 49.70%, and 207.61% respectively. This stagnation highlights the stock’s inability to generate capital appreciation over extended periods.

Technically, Amanta Healthcare is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a sustained bearish trend. The overall technical trend is classified as mildly bearish as of 12 Mar 2026, with immediate support at the new 52-week low of Rs.93.25 and resistance levels at Rs.103.42 (20-day moving average) and Rs.109.75 (100-day moving average).

Financial and Valuation Overview

Amanta Healthcare’s market capitalisation places it firmly in the micro-cap category. The company’s valuation multiples as of 12 Mar 2026 include a price-to-earnings (P/E) ratio of 37x and a price-to-book value (P/BV) of 1.82x. The enterprise value to EBITDA stands at 7.84x, while the EV to EBIT ratio is 11.34x. The EV to sales multiple is 1.70x, and the EV to capital employed ratio is 1.59x, indicating an attractive valuation relative to capital employed.

Dividend metrics are not applicable as the company has not declared dividends recently, with a dividend payout ratio of 0.0% and no dividend yield.

Despite the stock’s recent price weakness, the company reported positive quarterly financial results in December 2025. Net sales for the quarter reached a record Rs.74.49 crores, while operating profit to interest coverage ratio peaked at 3.04 times, signalling improved ability to meet interest obligations in the short term. The profit after tax (PAT) for the nine months ended December 2025 was Rs.10.75 crores, reflecting a robust growth rate of 73.88% compared to the previous period.

Quality and Credit Metrics

Amanta Healthcare’s overall quality grade remains below average, with a Mojo Score of 34.0 and a current Mojo Grade of Sell, upgraded from Strong Sell on 22 Dec 2025. The company’s long-term fundamentals show a negative compound annual growth rate (CAGR) of -2.00% in net sales over the past five years, indicating contraction in top-line revenue. EBIT growth over the same period was a modest 9.30%.

Capital structure metrics reveal moderate leverage, with an average debt to EBITDA ratio of 3.27 times and a net debt to equity ratio of 1.99, signalling relatively high financial risk. The average EBIT to interest coverage ratio is weak at 1.30x, although the recent quarterly improvement to 3.04x is notable. Return on capital employed (ROCE) averages 13.97%, while return on equity (ROE) is 8.18%, both considered weak relative to industry standards.

Institutional holdings stand at 12.34%, reflecting moderate participation from institutional investors. Importantly, there is no promoter share pledging, which mitigates some governance concerns.

Trading Activity and Delivery Volumes

Recent trading volumes have shown significant increases in delivery volumes, with a 1-day delivery change of 527.2% compared to the 5-day average and a 1-month delivery change of 93.09%. On 11 Mar 2026, the volume was 2.28 lakh shares, representing 64.33% of total traded volume, indicating heightened trading interest around the stock’s new low.

Despite this, the stock’s price has continued to trend downward, reflecting persistent selling pressure.

Shareholding and Corporate Governance

The majority shareholding in Amanta Healthcare Ltd is held by promoters, who maintain full control without any pledging of shares. This ownership structure provides stability in governance, although the company’s financial performance and market valuation have not reflected this advantage.

Tax ratio stands at 28.62%, consistent with industry norms, while the company has maintained a zero dividend payout ratio, indicating retention of earnings for reinvestment or debt servicing.

Summary of Key Challenges

Amanta Healthcare’s stock reaching an all-time low of Rs.93.25 underscores the challenges faced by the company in sustaining growth and market confidence. The negative sales growth over five years, coupled with moderate leverage and weak returns on capital, have contributed to subdued investor sentiment. Although recent quarterly results show improvement in profitability and interest coverage, these have not translated into positive price momentum.

The stock’s valuation multiples suggest some attractiveness relative to capital employed, but the overall quality indicators and financial metrics point to structural weaknesses that have weighed on the share price.

Trading volumes have increased sharply, reflecting active market participation, yet the price continues to test new lows, signalling ongoing caution among market participants.

Conclusion

Amanta Healthcare Ltd’s decline to a new all-time low is a significant event within the Pharmaceuticals & Biotechnology sector, highlighting the company’s struggles to generate sustained growth and shareholder returns. While quarterly financials indicate pockets of strength, the broader financial and technical indicators reveal a stock under pressure with limited upside momentum at present.

Investors and market watchers will continue to monitor the company’s financial trends and market behaviour closely as it navigates this challenging phase.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →